P2RX3 and hepatocellular carcinoma: Furthermore, the attenuation of P2X3 mediated proliferation by P2X3 antagonist, AF-353, clearly highlights the potential therapeutic application by pharmaceutical control of P2X3 receptor activation against HCC propagation.